A new study from NXT-USA has supported the use of Xeya Modern Shatavari in women with polycystic ovary syndrome (PCOS).
The randomised, double-blind, placebo-controlled trial examined outcomes related to ovarian health, hormonal balance and metabolic function.
Participants taking 100 mg of Xeya Modern Shatavari experienced significant improvements in somatic symptoms, such as hot flashes, fatigue and sleep disturbances, as well as in psychological symptoms, including mood swings, anxiety and brain fog, as measured by the validated Menopause Rating Scale.
Xeya Modern Shatavari is an ayurvedic adaptogen that is aimed at supporting reproductive health, PCOS support and relief during perimenopause and menopause.
Standardised to 15% shatavarins, Xeya delivers high potency at a low dose of just 50-100 mg.
Study findings
In women diagnosed with PCOS, Xeya Modern Shatavari was associated with improvements across multiple clinically relevant outcomes, including the following:
- Polycystic ovarian morphology,
- Androgen balance and hormone markers,
- Acne and hirsutism severity,
- Menstrual regularity.
All benefits were observed at just 100 mg per day, with excellent tolerability observed.
Why this matters
As demand grows for evidence-based PCOS solutions, clinicians and consumers are increasingly looking beyond symptom masking toward validated ingredients that support ovarian structure, hormones and metabolism together.
Women drive supplement adoption yet face persistent care gaps — high symptom burden, long diagnosis journeys and limited solutions that truly fit their lives.
Brands that deliver clinically supported relief at low doses earn trust, improve adherence and drive repeat purchases.